Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

被引：0

作者：

Sasaki, Koji ^{[1
]}

Rodriguez-Rivera, Ildefonso Ismael ^{[2
]}

Kantarjian, Hagop M. ^{[1
]}

O'Brien, Susan ^{[1
]}

Jabbour, Elias ^{[1
]}

Borthakur, Gautam ^{[1
]}

Ravandi, Farhad ^{[1
]}

Burke, Michael J. ^{[3
]}

Zweidler-McKay, Patrick A. ^{[1
]}

Cortes, Jorge E. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Texas Southwestern, Austin, TX USA

[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[11] The effectiveness of tyrosine kinase inhibitors and molecular response in newly diagnosed patients of chronic myeloid leukaemia
Fareed, N.
Somroo, N. M.
Quraishy, M. S.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 210 - 211
[12] Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Who Switch to Imatinib Following Optimal Response to Second Generation Tyrosine Kinase Inhibitors
Kota, Vamsi K.
Winton, Elliott F.
Arellano, Martha
Jillella, Anand
McLemore, Morgan L.
El Rassi, Fuad
Khoury, H. Jean
BLOOD, 2015, 126 (23)
[13] Complications of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia - Chronic Phase
Popovici, Despina Calamar
Ionita, Ioana
Nedelcu, Mirela
Ionita, Claudiu
Ionita, Hortensia
Moleriu, Radu Dumitru
Ilie, Calin Ovidiu
Iacob, Daniela
Constantin, Luca Tudor
Cheveresan, Adelina
Vaduva, Delia Berceanu
Radu, Daniela
REVISTA DE CHIMIE, 2019, 70 (08): : 3017 - 3020
[14] Second generation tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia
le Coutre, P.
Baskaynak, G.
Schwarz, M.
Petereit, C.
Westermann, J.
Dorken, B.
ANNALS OF ONCOLOGY, 2007, 18 : 17 - 17
[15] Long-term outcome of tyrosine kinase inhibitor treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic phase
Yong-Zhi Zheng
Jian Li
Cai Chen
Hao Zheng
Dan-Hui Fu
Jian-Da Hu
中华医学杂志英文版, 2021, 134 (24) : 3009 - 3011
[16] Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia
Ota, Shuichi
Matsukawa, Toshihiro
Yamamoto, Satoshi
Ito, Shinichi
Shindo, Motohiro
Sato, Kazuya
Kondo, Takeshi
Kohda, Kyuhei
Sakai, Hajime
Mori, Akio
Takahashi, Tohru
Ikeda, Hiroshi
Kuroda, Hiroyuki
Haseyama, Yoshihito
Yamamoto, Masaki
Sarashina, Takeo
Yoshida, Makoto
Kobayashi, Ryoji
Nishio, Mitsufumi
Ishihara, Toshimichi
Hirayama, Yasuo
Kakinoki, Yasutaka
Kobayashi, Hajime
Fukuhara, Takashi
Imamura, Masahiro
Kurosawa, Mitsutoshi
EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (01) : 95 - 105
[17] New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Kimura, Shinya
Ashihara, Eishi
Maekawa, Taira
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, 7 (05) : 371 - 379
[18] Long-term outcome of tyrosine kinase inhibitor treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic phase
Zheng, Yong-Zhi
Li, Jian
Chen, Cai
Zheng, Hao
Fu, Dan-Hui
Hu, Jian-Da
CHINESE MEDICAL JOURNAL, 2021, 134 (24) : 3009 - 3011
[19] Tyrosine kinase inhibitors in chronic myeloid leukemia
Sawyers, CL
Druker, B
CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (02): : 63 - 69
[20] First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia
Balsat, Marie
Alcazer, Vincent
Etienne, Gabriel
Huguet, Francoise
Berger, Marc
Cayssials, Emilie
Charbonnier, Aude
Escoffre-Barbe, Martine
Johnson-Ansah, Hyacinthe
Legros, Laurence
Roy, Lydia
Delmer, Alain
Ianotto, Jean-Christophe
Orvain, Corentin
Larosa, Fabrice
Meunier, Mathieu
Ame, Shanti
Andreoli, Annalisa
Cony-Makhoul, Pascale
Morisset, Stephane
Tigaud, Isabelle
Rea, Delphine
Nicolini, Franck Emmanuel
LEUKEMIA RESEARCH, 2023, 130

← 1 2 3 4 5 →